Johnson & Johnson (JNJ) 100.76 $JNJ
Global Elephantiasis (Lymphatic Filariasis) Therapeutics Pipeline Report 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bt9h9z/elephantiasis) has announced the addition of the "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - Eisai Co., Ltd. - Anacor Pharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/bt...phantiasis
Treatment Resistant Depression - Therapeutics Pipeline Review 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/l2gkp7/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Taisho Pharmaceutical Co., Ltd. - Avanir Pharmaceuticals, Inc. - Naurex, Inc. - MarcoPolo Pharmaceuticals SA - Edgemont Pharmaceuticals, LLC Scope - The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/l2gkp7/treatment
China fines eye-care companies on pricing charges
AP - Thu May 29, 11:34PM CDT
BEIJING (AP) — China has fined Johnson & Johnson, Nikon Corp. and five other makers of eyeglasses and contact lenses on price-fixing charges in its latest effort to use anti-monopoly law to control consumer prices.
Midday Glance: Pharmaceuticals companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Business Wire - Thu May 29, 7:01AM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that it has entered into an agreement granting Janssen Biotech, Inc. (Janssen) an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.
Insomnia - Pipeline Review, H1 2014: Includes 16 Company Profiles
M2 - Thu May 29, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lslnv2/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Abeille Pharmaceuticals - Actelion - Angelini - Eisai - Evotec - Grupo Ferrer Internacional - Heptares Therapeutics - Intec Pharma - IntelGenx - Intra-Cellular Therapies - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe Pharma - Neurim Pharmaceuticals - Novartis - Somnus Therapeutics For more information visit http://www.researchandmarkets.com/research/lslnv2/insomnia
United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report
M2 - Thu May 29, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4g2jmr/invitro) has announced the addition of Supplier Relations US, LLC's new report "United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing in-vitro (i.e., not taken internally) diagnostic substances, such as chemical, biological, or radioactive substances. The substances are used for diagnostic tests that are performed in test tubes, petri dishes, machines, and other diagnostic test-type devices. This latest In-Vitro Diagnostic Substance Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data, upstream and downstream industries, and trade data. This 2014 report's 174 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through December 2013. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/4g2jmr/invitro
United States Surgical and Medical Instrument Manufacturing Industry and its International Trade Report 2014 Edition
M2 - Thu May 29, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gx58k6/surgical_and) has announced the addition of Supplier Relations US, LLC's new report "Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing medical, surgical, ophthalmic, and veterinary instruments and apparatus (except electrotherapeutic, electromedical and irradiation apparatus). Examples of products made by these establishments are syringes, hypodermic needles, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers. The Surgical and Medical Instrument Manufacturing Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 174-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Boston Scientific Corporation - Bristol-Myers Squibb Company - C.R. Bard, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - General Electric Company - Hill-Rom - Hologic, Inc. - Hospira, Inc. - Johnson & Johnson - Pall Corporation - STERIS Corporation - Stryker Corporation - Teleflex Incorporated For more information visit http://www.researchandmarkets.com/research/gx...rgical_and
United States Surgical Appliance and Supplies Manufacturing Industry and its International Trade [2014 Edition]
M2 - Thu May 29, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bpjwbd/surgical) has announced the addition of Supplier Relations US, LLC's new report "Surgical Appliance and Supplies Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing surgical appliances and supplies. Examples of products made by these establishments are orthopedic devices, prosthetic appliances, surgical dressings, crutches, surgical sutures, and personal industrial safety devices (except protective eyewear). This 2014 publication of Surgical Appliance and Supplies Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Baxter International Inc. - Becton, Dickinson & Company - Boston Scientific Corporation - Cardinal Health, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - Hill-Rom - Intuitive Surgical, Inc. - Invacare Corporation - Johnson & Johnson - Kimberly-Clark Corporation - Kinetic Concepts, Inc. - Medtronic, Inc. - Mine Safety Appliances Company - Pall Corporation - Royal Philips Electronics - St. Jude Medical, Inc. - STERIS Corporation - Stryker Corporation - Synthes North America - Teleflex Incorporated - West Pharmaceutical Services, Inc. - Wright Medical Group, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/bpjwbd/surgical
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - Thu May 29, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Final Glance: Medical Devices companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
AbbVie Up on HCV Filing in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 2:04PM CDT
AbbVie Inc. (ABBV) filed new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy.
EU Nod for Eli Lilly/Boehringer's Jardiance (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 1:26PM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim announced that the European Commission (EC) has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance
Global Elephantiasis (Lymphatic Filariasis) Therapeutics Pipeline Report 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bt9h9z/elephantiasis) has announced the addition of the "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - Eisai Co., Ltd. - Anacor Pharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/bt...phantiasis
Treatment Resistant Depression - Therapeutics Pipeline Review 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/l2gkp7/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Taisho Pharmaceutical Co., Ltd. - Avanir Pharmaceuticals, Inc. - Naurex, Inc. - MarcoPolo Pharmaceuticals SA - Edgemont Pharmaceuticals, LLC Scope - The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/l2gkp7/treatment
China fines eye-care companies on pricing charges
AP - Thu May 29, 11:34PM CDT
BEIJING (AP) — China has fined Johnson & Johnson, Nikon Corp. and five other makers of eyeglasses and contact lenses on price-fixing charges in its latest effort to use anti-monopoly law to control consumer prices.
Midday Glance: Pharmaceuticals companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Business Wire - Thu May 29, 7:01AM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that it has entered into an agreement granting Janssen Biotech, Inc. (Janssen) an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.
Insomnia - Pipeline Review, H1 2014: Includes 16 Company Profiles
M2 - Thu May 29, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lslnv2/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Abeille Pharmaceuticals - Actelion - Angelini - Eisai - Evotec - Grupo Ferrer Internacional - Heptares Therapeutics - Intec Pharma - IntelGenx - Intra-Cellular Therapies - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe Pharma - Neurim Pharmaceuticals - Novartis - Somnus Therapeutics For more information visit http://www.researchandmarkets.com/research/lslnv2/insomnia
United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report
M2 - Thu May 29, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4g2jmr/invitro) has announced the addition of Supplier Relations US, LLC's new report "United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing in-vitro (i.e., not taken internally) diagnostic substances, such as chemical, biological, or radioactive substances. The substances are used for diagnostic tests that are performed in test tubes, petri dishes, machines, and other diagnostic test-type devices. This latest In-Vitro Diagnostic Substance Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data, upstream and downstream industries, and trade data. This 2014 report's 174 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through December 2013. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/4g2jmr/invitro
United States Surgical and Medical Instrument Manufacturing Industry and its International Trade Report 2014 Edition
M2 - Thu May 29, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gx58k6/surgical_and) has announced the addition of Supplier Relations US, LLC's new report "Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing medical, surgical, ophthalmic, and veterinary instruments and apparatus (except electrotherapeutic, electromedical and irradiation apparatus). Examples of products made by these establishments are syringes, hypodermic needles, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers. The Surgical and Medical Instrument Manufacturing Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 174-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Boston Scientific Corporation - Bristol-Myers Squibb Company - C.R. Bard, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - General Electric Company - Hill-Rom - Hologic, Inc. - Hospira, Inc. - Johnson & Johnson - Pall Corporation - STERIS Corporation - Stryker Corporation - Teleflex Incorporated For more information visit http://www.researchandmarkets.com/research/gx...rgical_and
United States Surgical Appliance and Supplies Manufacturing Industry and its International Trade [2014 Edition]
M2 - Thu May 29, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bpjwbd/surgical) has announced the addition of Supplier Relations US, LLC's new report "Surgical Appliance and Supplies Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing surgical appliances and supplies. Examples of products made by these establishments are orthopedic devices, prosthetic appliances, surgical dressings, crutches, surgical sutures, and personal industrial safety devices (except protective eyewear). This 2014 publication of Surgical Appliance and Supplies Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Baxter International Inc. - Becton, Dickinson & Company - Boston Scientific Corporation - Cardinal Health, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - Hill-Rom - Intuitive Surgical, Inc. - Invacare Corporation - Johnson & Johnson - Kimberly-Clark Corporation - Kinetic Concepts, Inc. - Medtronic, Inc. - Mine Safety Appliances Company - Pall Corporation - Royal Philips Electronics - St. Jude Medical, Inc. - STERIS Corporation - Stryker Corporation - Synthes North America - Teleflex Incorporated - West Pharmaceutical Services, Inc. - Wright Medical Group, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/bpjwbd/surgical
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - Thu May 29, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Final Glance: Medical Devices companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
AbbVie Up on HCV Filing in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 2:04PM CDT
AbbVie Inc. (ABBV) filed new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy.
EU Nod for Eli Lilly/Boehringer's Jardiance (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 1:26PM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim announced that the European Commission (EC) has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance
